Karen Silence

1.5k total citations
26 papers, 1000 citations indexed

About

Karen Silence is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Karen Silence has authored 26 papers receiving a total of 1000 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 7 papers in Oncology and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Karen Silence's work include Monoclonal and Polyclonal Antibodies Research (7 papers), Protease and Inhibitor Mechanisms (6 papers) and Blood properties and coagulation (3 papers). Karen Silence is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (7 papers), Protease and Inhibitor Mechanisms (6 papers) and Blood properties and coagulation (3 papers). Karen Silence collaborates with scholars based in Belgium, Netherlands and France. Karen Silence's co-authors include Christian Rolfo, Rob Fijnheer, Janine J. J. Hulstein, Peter J. Lenting, Patrick Pauwels, D Collen, Karen Zwaenepoel, Sylvie Rottey, Evelien Smits and Julie Jacobs and has published in prestigious journals such as Journal of Biological Chemistry, Circulation and Journal of Clinical Oncology.

In The Last Decade

Karen Silence

25 papers receiving 969 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Karen Silence Belgium	15	368	328	299	266	153	26	1000
Takaaki Hato Japan	17	242 0.7×	322 1.0×	210 0.7×	565 2.1×	104 0.7×	83	1.2k
Joan Somja Belgium	21	397 1.1×	452 1.4×	542 1.8×	129 0.5×	77 0.5×	56	1.5k
Martin D. Phillips United States	12	144 0.4×	153 0.5×	349 1.2×	192 0.7×	98 0.6×	16	978
Ghislaine Bernard France	20	523 1.4×	511 1.6×	226 0.8×	110 0.4×	81 0.5×	28	1.5k
Gijsbert C. de Gast Netherlands	19	401 1.1×	204 0.6×	374 1.3×	182 0.7×	118 0.8×	39	990
M. Testi Italy	19	174 0.5×	289 0.9×	244 0.8×	183 0.7×	41 0.3×	62	983
Jason Stadanlick United States	21	1.0k 2.7×	246 0.8×	246 0.8×	99 0.4×	111 0.7×	32	1.6k
Hilde De Winter United States	11	810 2.2×	173 0.5×	117 0.4×	339 1.3×	188 1.2×	32	1.2k
Rik Schots Belgium	24	416 1.1×	541 1.6×	403 1.3×	779 2.9×	60 0.4×	63	1.5k
Jörg Westermann Germany	21	611 1.7×	338 1.0×	476 1.6×	340 1.3×	77 0.5×	85	1.2k

Countries citing papers authored by Karen Silence

Since Specialization

Citations

This map shows the geographic impact of Karen Silence's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karen Silence with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karen Silence more than expected).

Fields of papers citing papers by Karen Silence

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karen Silence. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karen Silence. The network helps show where Karen Silence may publish in the future.

Co-authorship network of co-authors of Karen Silence

This figure shows the co-authorship network connecting the top 25 collaborators of Karen Silence. A scholar is included among the top collaborators of Karen Silence based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karen Silence. Karen Silence is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lim, Jamie, Jaap J. Plomp, Dana L.E. Vergoossen, et al.. (2023). Development and characterization of agonistic antibodies targeting the Ig-like 1 domain of MuSK. Scientific Reports. 13(1). 7478–7478. 4 indexed citations

Aftimos, Philippe, Christian Rolfo, Sylvie Rottey, et al.. (2017). Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies. Clinical Cancer Research. 23(21). 6411–6420. 47 indexed citations

Hultberg, Anna, Domenica Gandini, M. Bagot, et al.. (2017). CD70 EXPRESSION IN CUTANEOUS T CELL LYMPHOMA (CTCL) PATIENTS AND MECHANISMS OF ACTION OF ARGX‐110 IN SKIN: HISTOPATHOLOGICAL AND CLINICAL DATA. Hematological Oncology. 35(S2). 275–275. 5 indexed citations

Jacobs, Julie, Vanessa Deschoolmeester, Christian Rolfo, et al.. (2017). Preclinical data on the combination of cisplatin and anti-CD70 therapy in non-small cell lung cancer as an excellent match in the era of combination therapy. Oncotarget. 8(43). 74058–74067. 9 indexed citations

Michot, Jean‐Marie, Marie Maerevoet, Philippe Aftimos, et al.. (2016). Clinical response observed in a phase I study in T cell lymphoma patients treated with anti-CD70 SIMPLE Antibody ARGX-110.. Journal of Clinical Oncology. 34(15_suppl). 7556–7556. 3 indexed citations

Jacobs, Julie, Vanessa Deschoolmeester, Karen Zwaenepoel, et al.. (2015). CD70: An emerging target in cancer immunotherapy. Pharmacology & Therapeutics. 155. 1–10. 142 indexed citations

Awada, Ahmad, Christian Rolfo, Sylvie Rottey, et al.. (2014). A phase I, first-in-human study of ARGX-110, a monoclonal antibody targeting CD70, a receptor involved in immune escape and tumor growth in patients with solid and hematologic malignancies.. Journal of Clinical Oncology. 32(15_suppl). 3023–3023. 10 indexed citations

El‐Mesery, Mohamed, et al.. (2014). CD70-restricted specific activation of TRAILR1 or TRAILR2 using scFv-targeted TRAIL mutants. Cell Death and Disease. 5(1). e1035–e1035. 30 indexed citations

Silence, Karen, Torsten Dreier, Mahan Moshir, et al.. (2013). ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade. mAbs. 6(2). 523–532. 76 indexed citations

10.

Hulstein, Janine J. J., Pieter J. van Runnard Heimel, Arie Franx, et al.. (2006). Acute activation of the endothelium results in increased levels of active von Willebrand factor in hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome. Journal of Thrombosis and Haemostasis. 4(12). 2569–2575. 82 indexed citations

11.

Silence, Karen, Heidi Jonckheere, Peter Casteels, et al.. (2006). ALX-0081 Nanobody™, an Engineered Bivalent Anti-Thrombotic Drug Candidate with Improved Efficacy and Safety as Compared to the Marketed Drugs.. Blood. 108(11). 896–896. 2 indexed citations

12.

Hulstein, Janine J. J., Philip G. de Groot, Karen Silence, et al.. (2005). A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B. Blood. 106(9). 3035–3042. 109 indexed citations

13.

Lijnen, H.R., Karen Silence, Manfred Hartmann, et al.. (1996). Fibrinolytic properties of staphylokinase mutants obtained by ‘clustered charge-to-alanine’ mutagenesis. Fibrinolysis and Proteolysis. 10(3). 177–182. 1 indexed citations

14.

Silence, Karen, Manfred Hartmann, Karl‐Heinz Gührs, et al.. (1995). Structure-Function Relationships in Staphylokinase as Revealed by "Clustered Charge to Alanine" Mutagenesis. Journal of Biological Chemistry. 270(45). 27192–27198. 36 indexed citations

15.

Ueshima, Shigeru, Karen Silence, D Collen, Osamu Matsuo, & Roger Lijnen. (1993). Molecular conversions of recombinant staphylokinase in purified systems and in human plasma during plasminogen activation. Thrombosis and Haemostasis. 69(6). 822–822. 1 indexed citations

16.

Ueshima, Shigeru, Karen Silence, D Collen, & H.R. Lijnen. (1993). Molecular Conversions of Recombinant Staphylokinase During Plasminogen Activation in Purified Systems and in Human Plasma. Thrombosis and Haemostasis. 70(3). 495–499. 9 indexed citations

17.

Silence, Karen, Désiré Collen, & HR Lijnen. (1993). Regulation by alpha 2-antiplasmin and fibrin of the activation of plasminogen with recombinant staphylokinase in plasma. Blood. 82(4). 1175–1183. 22 indexed citations

18.

Silence, Karen, D Collen, & H.R. Lijnen. (1993). Interaction between staphylokinase, plasmin(ogen), and alpha 2-antiplasmin. Recycling of staphylokinase after neutralization of the plasmin-staphylokinase complex by alpha 2-antiplasmin. Journal of Biological Chemistry. 268(13). 9811–9816. 39 indexed citations

19.

Collen, D, Karen Silence, E Demarsin, M De Mol, & H.R. Lijnen. (1992). Isolation and characterisation of natural and recombinant staphylokinase. Fibrinolysis and Proteolysis. 6(4). 203–213. 53 indexed citations

20.

Silence, Karen, et al.. (1992). Fluorescence stopped-flow study of the interaction of tubulin with the antimitotic drug MDL 27048. Biochemistry. 31(45). 11133–11137. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact